- Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
- Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
- Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
- Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
- Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
- Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
- Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
- Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
- Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
More ▼
Key statistics
On Friday, Axsome Therapeutics Inc (AXSM:NMQ) closed at 71.71, 30.33% above the 52 week low of 55.02 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 70.97 |
---|---|
High | 72.43 |
Low | 69.70 |
Bid | 71.00 |
Offer | 72.75 |
Previous close | 71.52 |
Average volume | 553.38k |
---|---|
Shares outstanding | 47.37m |
Free float | 38.22m |
P/E (TTM) | -- |
Market cap | 3.39bn USD |
EPS (TTM) | -5.20 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
More ▼